Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Luana Lugini, Cristina Federici, Martina Borghi, Tommaso Azzarito, Maria Lucia Marino, Albino Cesolini, Enrico Pierluigi Spugnini & Stefano Fais. (2016) Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry 31:4, pages 538-545.
Read now
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Read now
Articles from other publishers (19)
Joelle Obeid, Abdullah Shaito, Hiba El Hajj, Carine Deleuze‑masquefa, Pierre-Antoine Bonnet, Marwan El‑Sabban & Jessica Saliba. (2023) Biological applications of imiquimod analogues: An update (Review). World Academy of Sciences Journal 5:3.
Crossref
Crossref
Fei Du, Lu-han Yang, Jiao Liu, Jian Wang, Lianpeng Fan, Suwit Duangmano, Hao Liu, Minghua Liu, Jun Wang, Xiaolin Zhong, Zhuo Zhang & Fang Wang. (2023) The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. Journal of Translational Medicine 21:1.
Crossref
Crossref
Azadeh Rahimi, Yasaman Esmaeili, Nasim Dana, Arezou Dabiri, Ilnaz Rahimmanesh, Setareh Jandaghain, Golnaz Vaseghi, Laleh Shariati, Ali Zarrabi, Shaghayegh Haghjooy Javanmard & Marco Cordani. (2023) A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma. European Journal of Pharmaceutical Sciences, pages 106476.
Crossref
Crossref
艳琳 谢. (2022) Progress in the Treatment of Advanced Melanoma. Advances in Clinical Medicine 12:06, pages 5256-5262.
Crossref
Crossref
Alice Indini, Alberto S. Pappo, Thomas K. Eigentler, Paola Collini & Andrea Ferrari. 2022. Rare Tumors in Children and Adolescents. Rare Tumors in Children and Adolescents
487
510
.
A.G. Nerkar. (2021) Metastatic melanomas: Treatment overview. Current Trends in Pharmacy and Pharmaceutical Chemistry 3:4, pages 50-55.
Crossref
Crossref
Siddhartha Sood, Rahul Jayachandiran & Siyaram Pandey. (2021) Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies 20, pages 153473542199007.
Crossref
Crossref
Mantas Janavicius, Nadezda Lachej, Giedre Anglickiene, Ieva Vincerzevskiene & Birute Brasiuniene. (2020) Outcomes of Treatment for Melanoma Brain Metastases. Journal of Skin Cancer 2020, pages 1-10.
Crossref
Crossref
Alice Indini, Ines Brecht, Michele Del Vecchio, Iyad Sultan, Stefano Signoroni & Andrea Ferrari. (2018) Cutaneous melanoma in adolescents and young adults. Pediatric Blood & Cancer 65:11, pages e27292.
Crossref
Crossref
Martina Sanlorenzo, Igor Vujic, Arianna Floris, Mauro Novelli, Loretta Gammaitoni, Lidia Giraudo, Marco Macagno, Valeria Leuci, Ramona Rotolo, Chiara Donini, Marco Basiricò, Pietro Quaglino, Maria Teresa Fierro, Silvia Giordano, Maria Sibilia, Fabrizio Carnevale-Schianca, Massimo Aglietta & Dario Sangiolo. (2018) BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody. Clinical Cancer Research 24:14, pages 3377-3385.
Crossref
Crossref
N. S. Saprykina, L. M. Borisova, M. P. Kiseleva, V. P. Krasnov, G. L. Levit, V. V. Musiyak, M. A. Baryshnikova, V. M. Bukhman & Z. S. Shprakh. (2017) Antitumor activity of ormustine against transplantable solid murine tumors. Part I. Russian Journal of Biotherapy 16:4, pages 55-60.
Crossref
Crossref
Teodora Nikolova, Wynand P. Roos, Oliver H. Krämer, Herwig M. Strik & Bernd Kaina. (2017) Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1868:1, pages 29-39.
Crossref
Crossref
Anfernee Kai-Wing Tse, Ying-Jie Chen, Xiu-Qiong Fu, Tao Su, Ting Li, Hui Guo, Pei-Li Zhu, Hiu-Yee Kwan, Brian Chi-Yan Cheng, Hui-Hui Cao, Sally Kin-Wah Lee, Wang-Fun Fong & Zhi-Ling Yu. (2017) Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biology 11, pages 562-576.
Crossref
Crossref
Olivier Michielin & Christoph Hoeller. (2015) Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treatment Reviews 41:8, pages 660-670.
Crossref
Crossref
Enrique Espinosa, Jean-Jacques Grob, Reinhard Dummer, Piotr Rutkowski, Caroline Robert, Helen Gogas, Richard Kefford, Alexander M. M. Eggermont, Salvador Martin Algarra, Axel Hauschild & Dirk Schadendorf. (2015) Treatment Algorithms in Stage IV Melanoma. American Journal of Therapeutics 22:1, pages 61-67.
Crossref
Crossref
Wynand P. Roos, Steve Quiros, Andrea Krumm, Stephanie Merz, Olivier Jérôme Switzeny, Markus Christmann, Carmen Loquai & Bernd Kaina. (2014) B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Oncotarget 5:24, pages 12607-12620.
Crossref
Crossref
Sarah Nicholas, Dimitrios Mathios, Christopher Jackson & Michael Lim. (2013) Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. Current Treatment Options in Oncology 14:2, pages 264-279.
Crossref
Crossref
Xavier Durando, Sandrine Mansard, Amaury Daste, Pierre Gimbergues, Laura Brocard, Nicolas Magné & Emilie Thivat. (2013) Stratégies thérapeutiques et traitements systémiques des métastases cérébrales du mélanome. Bulletin du Cancer 100:1, pages 23-28.
Crossref
Crossref
Anna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, Mario Santinami, Pier Francesco Ferrucci, Diana Giannarelli, Antonella Marasco, Licia Rivoltini, Ester Simeone, Stefania VL Nicoletti, Ester Fonsatti, Diego Annesi, Paola Queirolo, Alessandro Testori, Ruggero Ridolfi, Giorgio Parmiani & Michele Maio. (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. The Lancet Oncology 13:9, pages 879-886.
Crossref
Crossref